Last August, the FDA announced that is was granting the pharmaceutical supply chain a one year reprieve on complying with DSCSA.  The expectation is that the additional time would allow the industry to invest and test this new electronic interoperable system for tracing drugs through the supply chain.  This session will highlight how one chain is working through the process to comply with the law and they will share what they have learned and what is left to accomplish.